Poupardin et al., 2021 - Google Patents
Adherence to minimal experimental requirements for defining extracellular vesicles and their functionsPoupardin et al., 2021
View HTML- Document ID
- 2853928185156940039
- Author
- Poupardin R
- Wolf M
- Strunk D
- Publication year
- Publication venue
- Advanced Drug Delivery Reviews
External Links
Snippet
Rigorous measures are required to cope with the advance of extracellular vesicle (EV) research, from 183 studies published in 2012 to 2,309 studies published in 2020. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for …
- 238000010192 crystallographic characterization 0 abstract description 50
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/536—Immunoassay; Biospecific binding assay with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Poupardin et al. | Adherence to minimal experimental requirements for defining extracellular vesicles and their functions | |
Welsh et al. | Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches | |
Sluijter et al. | Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology | |
Ter-Ovanesyan et al. | Framework for rapid comparison of extracellular vesicle isolation methods | |
De Sousa et al. | Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy | |
Soekmadji et al. | The future of Extracellular Vesicles as Theranostics–an ISEV meeting report | |
Butt et al. | A molecular mechanism explaining albuminuria in kidney disease | |
Brown et al. | Hidden killers: human fungal infections | |
Karimi et al. | Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins | |
Onódi et al. | Isolation of high-purity extracellular vesicles by the combination of iodixanol density gradient ultracentrifugation and bind-elute chromatography from blood plasma | |
Iwai et al. | Isolation of human salivary extracellular vesicles by iodixanol density gradient ultracentrifugation and their characterizations | |
Hollander et al. | High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome | |
Dear et al. | Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling | |
Mathivanan et al. | Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature | |
Yuana et al. | Cryo-electron microscopy of extracellular vesicles in fresh plasma | |
Grigor’Eva et al. | Contamination of exosome preparations, isolated from biological fluids | |
Wang et al. | Human CD4+ lymphocytes for antigen quantification: characterization using conventional flow cytometry and mass cytometry | |
Bulgarelli et al. | Dendritic cell vaccination in metastatic melanoma turns “non-T cell inflamed” into “T-cell inflamed” tumors | |
Philogene et al. | Differential effect of bortezomib on HLA class I and class II antibody | |
US12038434B2 (en) | Devices, solutions and methods for sample collection related applications, analysis and diagnosis | |
Kaddour et al. | The past, the present, and the future of the size exclusion chromatography in extracellular vesicles separation | |
Anderson et al. | Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma | |
Nelson et al. | Measurement and standardization challenges for extracellular vesicle therapeutic delivery vectors | |
Tang et al. | Bronchus-associated macrophages efficiently capture and present soluble inhaled antigens and are capable of local Th2 cell activation | |
Fourtounas et al. | Different immunosuppressive combinations on T-cell regulation in renal transplant recipients |